Lyra Therapeutics (LYRA) Accounts Payables (2019 - 2025)

Lyra Therapeutics has reported Accounts Payables for 7 years, with the latest figure at $663000.0 in Q4 2025.

• On a quarterly basis, Accounts Payables fell 43.77% year-over-year to $663000.0 in Q4 2025; TTM through Dec 2025 was $663000.0, a 43.77% decrease from a year earlier, with the FY2025 full-year figure at $663000.0, down 43.77% from the prior year.
• Accounts Payables was $663000.0 for Q4 2025 at Lyra Therapeutics, up from $627000.0 in the prior quarter.
• The five-year high for Accounts Payables was $5.1 million in Q3 2023, with the low at $627000.0 in Q3 2025.
• Average Accounts Payables over 5 years is $2.5 million, with a median of $2.5 million recorded in 2022.
• The sharpest annual moves came in 2021 and 2025: Accounts Payables soared 449.43% in 2021, then sank 86.32% in 2025.
• Over 5 years, Accounts Payables stood at $3.1 million in 2021, then dropped by 16.29% to $2.6 million in 2022, then rose by 19.69% to $3.1 million in 2023, then slumped by 62.34% to $1.2 million in 2024, then plunged by 43.77% to $663000.0 in 2025.
• The last three Accounts Payables figures came in at $663000.0 (Q4 2025), $627000.0 (Q3 2025), and $680000.0 (Q2 2025), per Business Quant data.